

World Journal of *Clinical Cases*

World J Clin Cases 2022 October 16; 10(29): 10391-10822



Contents

Thrice Monthly Volume 10 Number 29 October 16, 2022

STANDARD AND CONSENSUS

- 10391** Baishideng's Reference Citation Analysis database announces the first Article Influence Index of multidisciplinary scholars

Wang JL, Ma YJ, Ma L, Ma N, Guo DM, Ma LS

REVIEW

- 10399** Cholecystectomy for asymptomatic gallstones: Markov decision tree analysis

Lee BJH, Yap QV, Low JK, Chan YH, Shelat VG

- 10413** Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria

Ince V, Sahin TT, Akbulut S, Yilmaz S

MINIREVIEWS

- 10428** Prostate only radiotherapy using external beam radiotherapy: A clinician's perspective

Lee JW, Chung MJ

ORIGINAL ARTICLE

Retrospective Study

- 10435** Age-adjusted NT-proBNP could help in the early identification and follow-up of children at risk for severe multisystem inflammatory syndrome associated with COVID-19 (MIS-C)

Rodriguez-Gonzalez M, Castellano-Martinez A

- 10451** Clinicopathological characteristics and prognosis of gastric signet ring cell carcinoma

Tian HK, Zhang Z, Ning ZK, Liu J, Liu ZT, Huang HY, Zong Z, Li H

- 10467** Development and validation of a prognostic nomogram for decompensated liver cirrhosis

Zhang W, Zhang Y, Liu Q, Nie Y, Zhu X

Observational Study

- 10478** Effect of medical care linkage-continuous management mode in patients with posterior circulation cerebral infarction undergoing endovascular interventional therapy

Zhu FX, Ye Q

- 10487** Effect of the COVID-19 pandemic on patients with presumed diagnosis of acute appendicitis

Akbulut S, Tuncer A, Ogut Z, Sahin TT, Koc C, Guldogan E, Karabulut E, Tanriverdi ES, Ozer A

EVIDENCE-BASED MEDICINE

- 10501** Delineation of a SMARCA4-specific competing endogenous RNA network and its function in hepatocellular carcinoma

Zhang L, Sun T, Wu XY, Fei FM, Gao ZZ

SYSTEMATIC REVIEWS

- 10516** Comparison of laboratory parameters, clinical symptoms and clinical outcomes of COVID-19 and influenza in pediatric patients: A systematic review and meta-analysis

Yu B, Chen HH, Hu XF, Mai RZ, He HY

CASE REPORT

- 10529** Surgical treatment of bipolar segmental clavicle fracture: A case report

Liang L, Chen XL, Chen Y, Zhang NN

- 10535** Multiple disciplinary team management of rare primary splenic malignancy: Two case reports

Luo H, Wang T, Xiao L, Wang C, Yi H

- 10543** Klippel-Trenaunay-Weber syndrome with ischemic stroke: A case report

Lee G, Choi T

- 10550** Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports

Zhang Z, Zheng CQ

- 10559** Novel way of patent foramen ovale detection and percutaneous closure by intracardiac echocardiography: A case report

Han KN, Yang SW, Zhou YJ

- 10565** Treatment failure in a patient infected with *Listeria* sepsis combined with latent meningitis: A case report

Wu GX, Zhou JY, Hong WJ, Huang J, Yan SQ

- 10575** Three-in-one incidence of hepatocellular carcinoma, cholangiocellular carcinoma, and neuroendocrine carcinoma: A case report

Wu Y, Xie CB, He YH, Ke D, Huang Q, Zhao KF, Shi RS

- 10583** Intestinal microbiome changes in an infant with right atrial isomerism and recurrent necrotizing enterocolitis: A case report and review of literature

Kaplina A, Zaikova E, Ivanov A, Volkova Y, Alkhova T, Nikiforov V, Latypov A, Khavkina M, Fedoseeva T, Pervunina T, Skorobogatova Y, Volkova S, Ulyantsev V, Kalinina O, Sitkin S, Petrova N

- 10600** *Serratia fonticola* and its role as a single pathogen causing emphysematous pyelonephritis in a non-diabetic patient: A case report

Villasuso-Alcocer V, Flores-Tapia JP, Perez-Garfias F, Rochel-Perez A, Mendez-Dominguez N

- 10606** Cardiac myxoma shedding leads to lower extremity arterial embolism: A case report

Meng XH, Xie LS, Xie XP, Liu YC, Huang CP, Wang LJ, Zhang GH, Xu D, Cai XC, Fang X

- 10614** Extracorporeal membrane oxygenation in curing a young man after modified Fontan operation: A case report
Guo HB, Tan JB, Cui YC, Xiong HF, Li CS, Liu YF, Sun Y, Pu L, Xiang P, Zhang M, Hao JJ, Yin NN, Hou XT, Liu JY
- 10622** Wandering small intestinal stromal tumor: A case report
Su JZ, Fan SF, Song X, Cao LJ, Su DY
- 10629** Acute mesenteric ischemia secondary to oral contraceptive-induced portomesenteric and splenic vein thrombosis: A case report
Zhao JW, Cui XH, Zhao WY, Wang L, Xing L, Jiang XY, Gong X, Yu L
- 10638** Perioperative anesthesia management in pediatric liver transplant recipient with atrial septal defect: A case report
Liu L, Chen P, Fang LL, Yu LN
- 10647** Multiple tophi deposits in the spine: A case report
Chen HJ, Chen DY, Zhou SZ, Chi KD, Wu JZ, Huang FL
- 10655** Myeloproliferative neoplasms complicated with β -thalassemia: Two case report
Xu NW, Li LJ
- 10663** Synchronous renal pelvis carcinoma associated with small lymphocytic lymphoma: A case report
Yang HJ, Huang X
- 10670** *Leclercia adecarboxylata* infective endocarditis in a man with mitral stenosis: A case report and review of the literature
Tan R, Yu JQ, Wang J, Zheng RQ
- 10681** Progressive ataxia of cerebrotendinous xanthomatosis with a rare c.255+1G>T splice site mutation: A case report
Chang YY, Yu CQ, Zhu L
- 10689** Intravesical explosion during transurethral resection of bladder tumor: A case report
Xu CB, Jia DS, Pan ZS
- 10695** Submucosal esophageal abscess evolving into intramural submucosal dissection: A case report
Jiao Y, Sikong YH, Zhang AJ, Zuo XL, Gao PY, Ren QG, Li RY
- 10701** Immune checkpoint inhibitor-associated arthritis in advanced pulmonary adenocarcinoma: A case report
Yang Y, Huang XJ
- 10708** Chondroid syringoma of the lower back simulating lipoma: A case report
Huang QF, Shao Y, Yu B, Hu XP
- 10713** Tension-reduced closure of large abdominal wall defect caused by shotgun wound: A case report
Li Y, Xing JH, Yang Z, Xu YJ, Yin XY, Chi Y, Xu YC, Han YD, Chen YB, Han Y

- 10721** Myocardial bridging phenomenon is not invariable: A case report
Li HH, Liu MW, Zhang YF, Song BC, Zhu ZC, Zhao FH
- 10728** Recurrent atypical leiomyoma in bladder trigone, confused with uterine fibroids: A case report
Song J, Song H, Kim YW
- 10735** Eczema herpeticum *vs* dermatitis herpetiformis as a clue of dedicator of cytokinesis 8 deficiency diagnosis: A case report
Alshengeti A
- 10742** Cutaneous allergic reaction to subcutaneous vitamin K₁: A case report and review of literature
Zhang M, Chen J, Wang CX, Lin NX, Li X
- 10755** Perithyroidal hemorrhage caused by hydrodissection during radiofrequency ablation for benign thyroid nodules: Two case reports
Zheng BW, Wu T, Yao ZC, Ma YP, Ren J
- 10763** Malignant giant cell tumors of the tendon sheath of the right hip: A case report
Huang WP, Gao G, Yang Q, Chen Z, Qiu YK, Gao JB, Kang L
- 10772** Atypical Takotsubo cardiomyopathy presenting as acute coronary syndrome: A case report
Wang ZH, Fan JR, Zhang GY, Li XL, Li L
- 10779** Secondary light chain amyloidosis with Waldenström's macroglobulinemia and internodal marginal zone lymphoma: A case report
Zhao ZY, Tang N, Fu XJ, Lin LE
- 10787** Bilateral occurrence of sperm granulomas in the left spermatic cord and on the right epididymis: A case report
Ly DY, Xie HJ, Cui F, Zhou HY, Shuang WB
- 10794** Glucocorticoids combined with tofacitinib in the treatment of Castleman's disease: A case report
Liu XR, Tian M
- 10803** Giant bilateral scrotal lipoma with abnormal somatic fat distribution: A case report
Chen Y, Li XN, Yi XL, Tang Y
- 10811** Elevated procalcitonin levels in the absence of infection in procalcitonin-secreting hepatocellular carcinoma: A case report
Zeng JT, Wang Y, Wang Y, Luo ZH, Qing Z, Zhang Y, Zhang YL, Zhang JF, Li DW, Luo XZ

LETTER TO THE EDITOR

- 10817** "Helicobacter pylori treatment guideline: An Indian perspective": Letter to the editor
Swarnakar R, Yadav SL
- 10820** Effect of gender on the reliability of COVID-19 rapid antigen test among elderly
Nori W, Akram W

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Natalia Stepanova, DSc, MD, PhD, Academic Research, Chief Doctor, Full Professor, Department of Nephrology and Dialysis, State Institution "Institute of Nephrology of the National Academy of Medical Sciences of Ukraine", Kyiv 04050, Ukraine. nmstep88@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yin; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

October 16, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Cutaneous allergic reaction to subcutaneous vitamin K₁: A case report and review of literature

Miao Zhang, Jia Chen, Chun-Xiao Wang, Nai-Xuan Lin, Xin Li

Specialty type: Dermatology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Cheng TH, Taiwan;
Jovandarc M, Serbia

Received: May 31, 2022

Peer-review started: May 31, 2022

First decision: June 27, 2022

Revised: July 9, 2022

Accepted: August 23, 2022

Article in press: August 23, 2022

Published online: October 16, 2022



Miao Zhang, Chun-Xiao Wang, Nai-Xuan Lin, Xin Li, Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China

Miao Zhang, Chun-Xiao Wang, Nai-Xuan Lin, Xin Li, Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai 201203, China

Jia Chen, Department of Dermatopathology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China

Corresponding author: Xin Li, MD, PhD, Director, Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, No. 110 Ganhe Road, Shanghai 200437, China.

13661956326@163.com

Abstract

BACKGROUND

Vitamin K₁ (phytomenadione) is a fat-soluble naturally occurring vitamin that is widely used to treat certain coagulation disorders. Adverse cutaneous reactions to vitamin K₁ can occur; however, owing to its low incidence and considerable variability in presentation and morphology, its diagnosis can be easily overlooked. Managing these reactions may be challenging for patients and clinicians. Therefore, reviewing the adverse cutaneous reactions to vitamin K₁ is important.

CASE SUMMARY

Here we report the case of a 50-year-old woman with no pre-existing hepatic disease who developed a cutaneous allergic reaction to subcutaneous vitamin K₁ that presented as localized eczematous plaques at the vitamin K₁ injection site. The eruption developed within 5 d of the injection and persisted for 32 mo despite treatment with topical and intralesional steroids. Eczema was diagnosed based on the results of the pathological examination, immunohistochemical staining, and a skin biopsy. The patient was advised to take herbal medicines orally twice daily. After treatment and follow-up, the patient's eczematous urticarial plaques improved and her condition stabilized.

CONCLUSION

Here we present the first case of a cutaneous allergic reaction to subcutaneous vitamin K₁ that was successfully treated with Chinese medicine.

Key Words: Vitamin K₁; Subcutaneous injection; Adverse reactions; Herbal medicine; Polyoxyethylated castor oil; Case report guidelines; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Adverse cutaneous reactions to vitamin K₁ can occur; however, their diagnosis can easily be overlooked. Managing these reactions may be challenging for both patients and clinicians. Here we report a patient who developed a cutaneous allergic reaction to subcutaneous vitamin K₁ that was successfully treated with herbal medicine, suggesting that Chinese medicine therapy may be a feasible way to treat adverse cutaneous reactions. We confirmed our clinical findings through physical examination, a skin biopsy, and immunohistochemical staining. We also conducted a literature review of eczematous-type reactions to clarify the possible pathogenesis and provoke new thinking regarding the clinical treatment of this disease.

Citation: Zhang M, Chen J, Wang CX, Lin NX, Li X. Cutaneous allergic reaction to subcutaneous vitamin K₁: A case report and review of literature. *World J Clin Cases* 2022; 10(29): 10742-10754

URL: <https://www.wjgnet.com/2307-8960/full/v10/i29/10742.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v10.i29.10742>

INTRODUCTION

Vitamin K₁, currently available for oral, intramuscular, subcutaneous, or intravenous administration, is generally well tolerated[1]. However, adverse effects of vitamin K₁ have rarely been observed and were mostly reported in the early 1960s in the European literature. The most important adverse effects of vitamin K₁ are hyperbilirubinemia and kernicterus in newborn infants[2], particularly in premature infants resulting from the competition for glucuronyl transferase in the presence of immature liver function[3].

Based on the characteristics of skin rashes, three types of adverse events can be caused by vitamin K₁ injection: (1) Localized pruritic erythematous, eczematous, indurated plaques (most common); (2) localized morphea-form eruptions (secondary to the eczematous type[4-8]); and (3) diffuse maculopapular eruptions (very rare), which were reported in early studies[9-11]. In accordance with the case report guidelines[12], here we present a case of a patient who developed an eczematous-type reaction to vitamin K₁ injection. Residual pigmentation persisted after 18 mo of treatment; however, the patient responded well to treatment with Chinese medicine (CM).

Cutaneous reactions caused by vitamin K₁ injections are mainly treated symptomatically. Most patients are treated with topical corticosteroids with or without occlusion and intralesional steroids; however, these treatments are ineffective. The topical application of tacrolimus (FK-506), a potent interleukin-2 and T-cell activation inhibitor, may become a future treatment option. Lauerma[13] demonstrated that topical tacrolimus pretreatment effectively suppresses allergic contact dermatitis caused by dinitrobutylphenol. However, its use for treating cutaneous hypersensitivity reactions to vitamin K₁ has not been reported.

Some researchers believe that the exacerbation of persistent eruptions may be related to dietary vitamin K. However, no follow-up investigation of this possibility is available in the English literature. This is probably due to difficulty avoiding dietary vitamin K₁, as small quantities are present in many different foods, with high concentrations in green leafy vegetables. Our patient failed to maintain a low vitamin K₁ diet due to food preferences. Hence, whether the minute quantities of vitamin K₁ present in some foods preclude the efficacy of dietary therapy remains unknown.

CASE PRESENTATION

Chief complaints

A 50-year-old woman was referred to our hospital on September 14, 2020 with the complaint of an intensely pruritic erythematous patch on her right hip.

History of present illness

The patient's symptom of an intensely pruritic erythematous patch started 1 year before presentation.

History of past illness

One year prior, the patient had received subcutaneous injections of vitamin K₁ 40 mg before thyroid nodule surgery to prevent bleeding. Five days after the injections, she developed the abovementioned symptoms at the injection site that caused discomfort without any obvious burning, pain, or other problems. She had not been treated with phytonadione, cyclosporine, or other medications containing polyoxyethylated castor oil (PEO-CO). She was diagnosed with urticaria, for which topical chlorphenicol betamethasone liniment, dexamethasone sodium phosphate, and chlorpheniramine maleate injections were prescribed. However, her condition did not improve substantially. Despite intermittent treatment for one year, her condition was not well controlled.

Personal and family history

The patient denied any family history of any hereditary disease.

Physical examination

A physical examination revealed an erythematous itchy-infiltrated area of approximately 10 cm × 10 cm on the right hip at the injection sites. The patient had a dry mouth, no sweat, and normal urine and bowel movements. Her tongue was red and covered with a thin and greasy coating, and her pulse was fine and rapid. Since the onset of the disease, she had no fever, chills, joint pain, swollen lymph nodes, weight loss, trauma, foreign body contact, or suspicious drug use. Her clinical symptoms of intense pruritus and weeping, erythematous, eczematous, and indurated plaques are shown in [Figure 1A](#) and [B](#).

Laboratory examinations

Liver ultrasonography findings and aspartate aminotransferase (serum glutamic oxaloacetic transaminase), alkaline phosphatase, and serum bilirubin levels were normal.

Skin biopsy

A clear diagnosis of the disease could not be made based on the clinical manifestations of the erythematous and eczematous plaques. The patient's skin lesions were nonspecific and could be easily confused with mycosis fungoides (MF). To ensure diagnostic accuracy, we performed a biopsy of the skin from the right hip during the examination, the results of which were available within a week. Considering the characteristics of the skin lesions, we temporarily suspected an adverse cutaneous reaction to vitamin K₁ (eczematous type), and the CM diagnosis was "wet sores." The tongue coating, pulse, and skin lesion characteristics were consistent with those of blood-heat syndrome. We considered blood heat and Yang floating as the main pathogeneses according to the CM theory.

Histological examination


The erythema area was reduced, the degree of itching was alleviated, and the patient's condition gradually stabilized by November 12, 2020. The patient's tongue was reddish with a white and greasy coating and her pulse was slippery. A skin biopsy was performed ([Figure 1C](#) and [D](#)), and a histological examination showed an intense perivascular infiltrate composed of lymphocytes and histiocytic cells with rare plasma cells and eosinophils. Prominent endothelial cell swelling was also observed. The infiltrate extended through the reticular dermis into the subcutaneous fat and focally surrounded the eccrine and neural structures. The lower half of the dermis was markedly sclerotic with thickened eosinophilic collagen bundles. These findings were consistent with our diagnosis.

Further diagnostic work-up

A microscopic examination revealed a normal epidermis and more lymphocytes infiltrating the blood vessels in the dermis, several of which mimicked Pautrier microabscesses ([Figure 1E](#) and [F](#)). Immunohistochemical (IHC) staining showed that T cells were positive for CD3, CD5, and CD4 and partially positive for CD8 ([Figure 2A-D](#)). B cells were positive for CD20 and CD79a ([Figure 2E](#) and [F](#)). Histocytes were positive for CD68, natural killer cells were positive for CD56, and mastocytes were negative for CD117 ([Figure 3A-C](#)). B cells tested positive for common acute lymphoblastic leukemia antigen (CD10), negative for platelet-endothelial cell adhesion molecule-1 was negative for (CD31), and negative for syndecan-1 (CD138) ([Supplementary Figure 1](#)). We ruled out MF because the IHC results suggested that the cells in this case were multi-lineage and polyclonal.

FINAL DIAGNOSIS

According to the clinical picture, histopathology results, and IHC results, the final diagnosis was a cutaneous allergic reaction to the vitamin K₁ injections.



DOI: 10.12998/wjcc.v10.i29.10742 Copyright ©The Author(s) 2022.

Figure 1 Clinical presentation and diagnostic clues from the original symptoms. A and B: Intensely pruritic, weeping, erythematous, eczematous, and indurated plaques; C: An intense perivascular infiltrate composed of lymphocytes and histiocytic cells, with rare plasma cells and eosinophils (hematoxylin–eosin stain, 100 ×); D: Prominent endothelial cell swelling. The infiltrate extended through the reticular dermis into the subcutaneous fat and focally surrounded the eccrine and neural structures (hematoxylin–eosin stain, 400 ×); E and F: The lower half of the dermis was markedly sclerotic with thickened eosinophilic collagen bundles. A microscopic examination revealed a normal epidermis and more lymphocytes infiltrating the blood vessels in the dermis, several of which were mimicking Pautrier microabscesses (100 ×).

TREATMENT

The patient was treated with an oral herbal medicine for “cooling blood and restraining Yang” twice daily, 30 min after meals. Our team previously reported that blood-cooling and Yang-restraining herbs had a positive clinical effect in the treatment of skin diseases such as blood-heat syndrome, eczema, and psoriasis vulgaris[14,15]. Other authors showed that the drug for cooling blood and restraining Yang may upregulate the expressions of PD-1 mRNA, PD-L2 mRNA, and their proteins in patients with psoriasis vulgaris, which manifests as blood-heat syndrome[16]. The specific compositions, dosages, and medicinal sources of these herbal decoctions are listed in Table 1.

OUTCOME AND FOLLOW-UP

The previous misdiagnosis was corrected in a timely manner. Nevertheless, the main components of the blood-cooling and yang-restraining herbal medicine remained unchanged. The dose of the drug was adjusted appropriately, and the patient continued to reduce her intake of leafy green vegetables.

Table 1 Details of the decoction for blood cooling and Yang restraining (translated in English)

Main composition	Chinese pinyin	Latin scientific name	Medicinal source	Crude drug content (g)
Radix Cyathulae	Chuan Niu Xi	<i>Cyathula officinalis Kuan</i>	Root	12
Rhizoma Alismatis	Ze Xie	<i>Alisma plantago-aquatica L</i>	Tuber	12
Belvedere fruit	Di Fu Zi	<i>Fructus Kochiae</i>	Fruit	15
Cortex	Bai Xian Pi	<i>Cortex dictamni</i>	Root bark	12
Mother of pearl	Zhen Zhu Mu	<i>Concha Margaritifera Usta</i>	Shell	30
Magnetite	Ci Shi	<i>Magnetium</i>	Fe ₃ O ₄	30
Liquorice	Gan Cao	<i>Glycyrrhiza uralensis Fisch</i>	Root	3
Herba Lycopi	Ze Lan	<i>Aconitum gymnandrum Maxim</i>	Leaf	9
Scutellaria baicalensis	Huang Qin	<i>Scutellaria baicalensis Georgi</i>	Root	12
Rehmannia	Di Huang	<i>Rehmannia glutinosa</i>	Root	15
Prepared rehmannia	Shu Di Huang	<i>Rehmannia glutinosa</i>	Root	15
Cortex Moutan	Mu Dan Pi	<i>Cortex Moutan Radicis</i>	Root bark	12
Red-rooted Salvia	Sheng Dan Shen	<i>Salvia miltiorrhiza Bge</i>	Root	15
Red peony	Chi Shao	<i>Radix Paeoniae Rubra</i>	Root	12
Sophorae Flavescentis	Ku Shen	<i>Sophora flavescens</i>	Root	12
Angelicae Sinensis	Guan Huang Bai	<i>Phellodendron amurense Rupr</i>	Bark	12

The patient was followed up on June 23, 2021, March 6, 2022, and April 2, 2022. After taking the herbal medicine, the patient's erythema area was reduced, the degree of itching was alleviated, and her symptoms improved significantly. Her tongue was still red with a thin and greasy coating and her pulse was fine and rapid; hence, the composition of the herbal medicine was adjusted accordingly. After taking the herbal medicine for 18 mo, her symptoms greatly improved with only a few residual pigments in the lesion area and no itching sensation. She stopped taking the oral herbal medicine in April 2022 in accordance with the doctor's advice.

At presentation, the patient showed some inconspicuous pigment residues with no itching sensation, and the lesions did not involve the internal organs or lymph nodes. Throughout the treatment and follow-up period, the patient showed good adherence to and tolerance of the CM therapy, and no adverse or unanticipated events occurred during this period. The patient's condition was well controlled, and her quality of life improved. She was regularly followed up at a local clinic, with no complaints of discomfort or adverse events during treatment. At the 18-mo follow-up, the eczematous erythema plaques on her right hip had notably improved compared to the pretreatment condition. However, the eruption persisted with occasional pruritus for approximately 32 mo. The patients' skin lesions before and after treatment are shown in [Figure 4A](#) and [B](#). The full timeline of diagnosis, medical treatment process, physical examination findings, clinical characteristics, and laboratory findings are shown in [Figure 5](#).

DISCUSSION

Our patient developed severe localized reactions at the site of the subcutaneous injections of vitamin K₁, and the lesions slowly subsided over a 32-mo period. Although the early changes resembled urticaria, they were not transient. Most importantly, the swollen red plaques involved underlying dermal involvement and epidermal changes. The diagnosis was confirmed by clinical imaging, histopathology, and IHC staining. The persistence of the pruritus in our patient may imply that the drug may have remained locally at the injection site or that an altered host tissue reaction in the skin may have provided a continued antigen stimulus.

We summarized the results of the 20 cases reported to date of eczematous-type reactions in [Table 2](#), including the administration route, dose, reaction, and diagnostic assessment, with the aim of determining the pathogenesis of this hypersensitivity. Several features of the eczematous reaction to vitamin K₁ suggest that it was a manifestation of delayed-type hypersensitivity, a prototype of type IV cell-mediated immunity. In most cases, lesions appeared approximately 7-10 d after the first dose of vitamin K₁ [17-36]. In addition, subsequent patch and intradermal testing produce a reaction within 3-5 and 1-2 d, respectively [17-21,23,25,26,31,32,34,36]. The time sequence of the development of these

Table 2 Details of case reports of reactions to vitamin K1 (eczematous type)

First author	Country	Date	Sex	Age (yr)	Adm.	Dose (mg)	Onset	Reaction Location/duration	Patch	I.c.	Other assessments	Comments	Outcome
Piguet <i>et al</i> [17]	France	1964	F	33	IM		Before surgery	Buttock/ wk	K ₁ -	K ₁ +		Alcoholic cirrhosis	
					IM			Buttock, chest, face/8 d					
Barnes <i>et al</i> [18]	United Kingdom	1976	F	31	IM	10	2 wk	Buttock/2 mo	ND	K ₁ +	Biopsy	Budd-Chiari syndrome, PCV	Plaques disappeared
			F	30	IM	100	Several weeks	Upper arm, thigh/2 mo				Drug overdose, renal failure, generalized rash	
Heydenreich <i>et al</i> [19]	Denmark	1977	F	51	IV	20 daily	8–10 d	Arms	K ₁ + ¹	K ₁ +	ST	Hepatitis, RA, GN	No skin problems
											Intracutaneous test, epicutaneous test		
Bullen <i>et al</i> [20]	United Kingdom	1978	F	17	INJ	340	13 d	Buttock/11 d	ND	K ₁ +, K ₄ - ¹	Biopsy	CAH	Resolution with scaling
			F	24	INJ	360	9 d	Buttock/9 d	ND	K ₁ +, K ₄ -	Biopsy	CAH	
			F	39	INJ	270	9 d	Buttock/19 d	ND	K ₁ +, K ₄ -	Biopsy	CAH, RA	
			F	50	INJ	440	16 d	Buttock/18 d	ND	ND	Biopsy	CAH, liver congestion, RA	
			F	48	INJ	300	10 d	Buttock/22 d	ND	K ₁ +, K ₄ -		Alcoholic cirrhosis	
			F	12	INJ	280	7 d	Buttock/9 d	ND	K ₁ +, K ₄ -	Biopsy	Congenital hepatic failure	
Robison <i>et al</i> [21]	United States	1978	M	63	IM	30	10 d	Upper arm	K ₁ + ¹	K ₁ + ¹	Biopsy	Alcoholic cirrhosis	Temporarily alleviated
											Epicutaneous test		
Jean-Pastor <i>et al</i> [22]	France	1981 ⁺											
Finkelstein <i>et al</i> [23]	Canada	1987	F	26	SC	280	11 d	Months	K ₁ -, K ₃ -	K ₁ +, K ₃ -	Biopsy	Metastatic cholangiocarcinoma	Hyperpigmentation remained
			F	42	SC	40	14 d	Months	K ₁ +, K ₃ -	ND	Biopsy	Primary biliary cirrhosis	Total bilirubin remained elevated
			F	39	IM	1750	2 d	Months	K ₁ -, K ₃ -	K ₁ +, K ₃ -	Biopsy	Chronic myeloid leukemia	Residual erythema scaling, pruritus, and hyperpigmentation
			M	51	SC	10	14 d	Months	K ₁ +, K ₃ -	K ₁ +, K ₃ -	Biopsy	Amyloidosis	Mild improvement
			F	64	SC	10	5 d	Months	K ₁ +, K ₃ -	ND	Biopsy	Cardiac cirrhosis	Persistent pruritus
			F	32	SC	10	14 d	Months	K ₁ -, K ₃ -	K ₁ +, K ₃ -	Biopsy	Preeclampsia with DIC	

Joyce <i>et al</i> [24]	United States	1988	F	36	IM	20	14 d	Right arm/4 yr		Biopsy	Long-term warfarin therapy	Intermittent pruritus and persistent induration
			F	61	IM	10	6 d	Left arm/6 mo		Biopsy	Severe cardiac disease	Skin lesion persisted unchanged
Sanders <i>et al</i> [25]	United States	1988	F	18	SC	100	> 10 d	Buttock, upper arm/weeks	K ₁ +, K ₄ -	Biopsy	Anorexia, N/V	Lesions resolved
			F	28	SC	10	2 wk	Arm/1 mo	K ₁ +, K ₄ -		Dilated cardiomyopathy	Slowly resolved
			F	31	SC		10 d	Upper arm/2 wk			Healthy	
			F	25	SC	40	After the injection	Weeks	K ₁ +, K ₄ -	Biopsy	Drug overdose, elevated LFT results	Rash cleared
Pigatto <i>et al</i> [26]	Italy	1990	F	9	IM		10 d	Buttocks	K ₁ +, K ₂ -, K ₃ -		Minor beta thalassemia Factor X deficiency	Some residual pigmentation
Lee <i>et al</i> [27]	United States	1992	F	49	SC	110	During treatment	Upper arms, thighs, and buttocks/2 mo		Biopsy	CAH, variceal bleeds	Total regression of lesions
Tuppai <i>et al</i> [28]	Canada	1992	M	45	SC	330	Few days	Upper arms and abdomen/2 mo		Biopsy	Long history of ethanol abuse	Resolution of skin eruption
Lemlich <i>et al</i> [29]	United States	1993	F	43		30	2 wk	6 mo		Biopsy	Budd-Chiari syndrome, PCV	No sclerodermatous changes
			F	62		20	2 wk	1 mo		Biopsy	Stage IV endometrial carcinoma	Mild postinflammatory hyperpigmentation remained
			F	57			2 wk	Right arm/1 mo		Biopsy	Stage II ovarian cancer	
			F	50			2 wk	Left upper arm		Biopsy	Healthy	Remained symptomatic
Bruynzeel <i>et al</i> [30]	Netherlands	1995	F	32	SC		2 wk	Right upper arm/2 mo	K ₁ -, K- K+	Biopsy	Pelvic vein thrombosis	Resolution
			F	44	SC		4 wk	Left upper leg/mo			Acute pancreatic <i>Ascaris lumbricoides</i> infection	Lesion persisted
Balato <i>et al</i> [31]	Italy	1998	F	49	IM	30		Right buttock/4 mo	K- K+	Biopsy		Lesion healed spontaneously
										Scratch-patch test		
										Prick test		
Wong <i>et al</i> [32]	Australia	1999	F	40	IM	40	5 d	Thighs/mo	K ₁ +, K ₃ + K1+		Cholelithiasis, asthma, duodenal ulcer, and esophagitis	Residual erythema persisted
Wilkins <i>et al</i> [33]	Canada	2000	F	50	SC	15	1 wk	Left arm/18 mo		Biopsy	Hypothyroidism,	Eruption persisted with

Sommer <i>et al</i> [34]	United Kingdom	2002	F	27	IM		1 d	Thigh/2 yr	K ₁ +, K ₄ +		superficial phlebitis	occasional flares
Bui <i>et al</i> [35]	United States	2004	F	21	SC	65	10 d	Arms, abdomen/19 d			CF, CF-related DM	Symptoms persisted
Giménez-Arnau <i>et al</i> [36]	Spain	2005	F	64	IM		1 wk	Buttock	K ₁ -	K ₁ +	Chronic hepatitis C virus liver disease	Rash disappeared
											Biopsy	Skin healed
											Immunoallergic study	
											Prick test	
Our case	China	2022	F	50	SC	40	5 d	Right hip			Biopsy	Multiple thyroid nodules
											IHC	A few residual pigments in the lesion area and no itching sensation


¹Patch or intracutaneous tests performed in controls.

+Six patients were reported as “personal observations” but no details were provided for individual patients.

CAH: Chronic active hepatitis; DIC: Disseminated intravascular coagulation; DM: Diabetes mellitus; GN: Glomerulonephritis; LFT: Liver function test; N/V: Nausea and vomiting; PCV: Polycythemia vera; RA: Rheumatoid arthritis; SLE: Systemic lupus erythematosus; CF: Cystic fibrosis; INJ: Injection; IHC: Immunohistochemical; Adm.: Administration; SC: Subcutaneous; IM: Intramuscular; IV: Intravenous; ND: No allergy tests performed; ST: Scratch test; Patch test: 2-4 d; Intracutaneous test: 1-4 d.

reactions corresponded well with type IV cell-mediated hypersensitivity. The positive results of sensitivity testing using patch test methods implied that sufficient antigens may have been absorbed to generate an immune response. Several patients exhibited a recall reaction[21,23,30] in previously affected areas compatible with the recall phenomenon in allergic contact eczema when antigens applied in new areas precipitate an eczematous flare-up. Several histopathological studies of biopsy specimens from the lesion and the intracutaneous test site showed spongiosis of the epidermis, dermal edema, and perivascular mononuclear and eosinophilic cellular infiltrates consistent with delayed-type hypersensitivity[18,20-25,27-31,33,36].

To identify the allergen, we summarized the reported cases that used patch and intradermal testing to delineate the mechanism of skin hypersensitivity to vitamin K₁. Previous studies consistently reported that only the whole preparation of vitamin K₁ (in its vehicle) or vitamin K₁ alone produced positive test results[19-21]. When the individual components of the vehicles were tested, they almost always yielded negative results. In some cases, patch tests showed negative results, while intradermal tests showed opposite results[23,30], which may, to some degree, reflect insufficient percutaneous absorption. Page *et al*[37] found that dermatitis from topically applied vitamin K₁ was caused by the chemical rather than the base. One study in Australia[32] illustrated the importance of testing with appropriate concentrations of reagents, as patch testing with Konakion Cremophor-EL 2 mg/mL showed a negative result, whereas testing with a 10 mg/mL concentration (the concentration administered at hospitals) showed a strongly positive result. Another study showed relatively high rates of intradermal positivity in control participants (4 of 10 controls)[20]; however, the reactions in controls were not as florid, and in two cases, the reaction was delayed to day 6, which may indicate sensitization.




DOI: 10.12998/wjcc.v10.i29.10742 Copyright ©The Author(s) 2022.

Figure 2 Immunohistochemical assay for positive phenotypes. A-D: T cells tested positive for CD3, CD5, and CD4 and partially positive for CD8 (200 ×); E and F: B cells tested positive for CD20 and CD79a (200 ×).

Previous reports suggested that the underlying cause of the reaction is not phytonadione but rather the vehicle, PEO-CO, which is used as a solubilizer or diluent for several drugs. Although experimental and clinical data are limited, these reactions have been classified as anaphylactoid reactions[38]. Experimental and other evidence suggested that PEO-CO may cause anaphylaxis by releasing histamine, as demonstrated by studies showing its pharmacological action in dogs[39], a memory-mediated reaction involving complement activation[40], and the presence of immunoglobulin G steroid sulfatase antibodies as confirmed by appropriate immunological tests[41]. However, PEO-CO may not be responsible for all anaphylactic events, as demonstrated by two cases of anaphylaxis after the administration of formulations that did not containing PEO-CO[42,43].


Several vitamin K preparations are available that contain different inactive ingredients. Most previous investigators did not use patches or intracutaneous testing for these additional ingredients of vitamin K₁. Five investigators tested the components of their particular preparations and obtained negative results[19,21,23,25,30]. These results suggest that the antigen that causes adverse cutaneous reactions is not the inactive ingredient in the mixture but vitamin K itself. Because of the potential for exacerbating the long-lived reactions in our patient, no patch or intracutaneous tests were performed.

Liver disease was previously believed to play a role in the pathogenesis of this allergic reaction[44]; however, six cases of cutaneous reactions to vitamin K₁ have been described in patients with no known liver disease[21,24,25]. One study in Japan showed, in 94 documented cases of cutaneous hypersensitivity reactions to vitamin K₁, no correlation between vitamin K₁ hypersensitivity and liver disease[10]. Nevertheless, as patients with liver disease account for the majority treatment demand for vitamin K₁, they may be at an increased risk of developing cutaneous reactions to it. An investigation into the



DOI: 10.12998/wjcc.v10.i29.10742 Copyright ©The Author(s) 2022.

Figure 3 Immunohistochemical assays for other phenotypes. A-C: Histocytes were positive for CD68+, natural killer cells tested positive for CD56, and mastocytes tested negative for CD117 (200 ×).



DOI: 10.12998/wjcc.v10.i29.10742 Copyright ©The Author(s) 2022.

Figure 4 Clinical presentation before and after treatment. A: Appearance of the skin before treatment (September 14, 2021); B: Appearance of the skin during follow-up (March 6, 2022). In the 1.5 years follow-up period, the area of erythema was reduced, the degree of itching was alleviated, and the patient's condition gradually stabilized.

underlying liver dysfunction may be indicated when a patient develops a local eczematous reaction to vitamin K₁.

In all reported cases of skin reactions, the dose range was 10-1750 mg[17-36]. One study[20] hypothesized that even a minimum dose can cause an eruption. Some researchers have noted that patients in some of the more recalcitrant cases received the smallest doses[33]. In addition, the dosage of vitamin K seems to have no correlation with the onset of the allergic reaction as confirmed by a study [45] that described sclerodermatous reactions associated with large doses of vitamin K₁ 100-500 mg. This finding suggests that neither injections nor large doses are required for a sclerodermatous reaction to occur[46]. Our patient had no evidence of preexisting hepatic disease and received a total dose of 40 mg.

CONCLUSION

Although the incidence of adverse reactions to the subcutaneous injection of vitamin K₁ is considerably




Figure 5 Case timeline. Important dates, times, and detailed diagnostic process during the treatment and follow-up period.

low, such adverse effects can be devastating. In our case, the patient experienced discomfort only in the area of the local lesions and the disease did not have a particularly serious impact on her daily life. Overall, the disease progressed slowly and was well controlled from onset to follow-up. However, it remains difficult to make an accurate clinical conclusion about this case of hypersensitivity, which creates new challenges and requirements for the diagnosis and treatment of such conditions that, in the future, may be avoided with a more judicious use of this form of vitamin K₁ in the clinical setting. In contrast to the previously reported cases, our patient was treated its CM. The key to CM treatment is to accurately identify the syndrome and treat the symptoms. CM may achieve unexpectedly good results in terms of improving the patient's condition. However, the efficacy, safety, and mechanisms of CM therapy require further investigation. Additionally, whether CM therapy alone or combined with Western medicine has better clinical efficacy for the treatment of these adverse reactions requires confirmation.

FOOTNOTES

Author contributions: Zhang M contributed to the manuscript writing and editing and the data collection; Chen J, Wang CX, and Lin NX contributed to the data analysis; Li X contributed to the study conceptualization and supervision; all authors have read and approved the final manuscript.

Informed consent statement: Written informed consent was obtained from the patient for the publication of this case and accompanying images.

Conflict-of-interest statement: The authors declare no conflicts of interest related to the publication of this report.

CARE Checklist (2016) statement: The authors read the CARE Checklist (2016) and prepared and revised the manuscript accordingly.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Miao Zhang 0000-0002-0340-2043; Jia Chen 0000-0002-7094-9460; Chun-Xiao Wang 0000-0002-5233-9079; Nai-Xuan Lin 0000-0002-6754-4606; Xin Li 0000-0003-2525-9679.

S-Editor: Zhang H

L-Editor: A

P-Editor: Zhang H

REFERENCES

- 1 **World Health Organization International Agency for Research on Cancer (IARC).** Vitamin K substances: IARC monograph. *IARC Monogr Eval Carcinog Risks Hum* 2000; **76**: 417-486
- 2 **De Jonge GA.** Vrochbeschadiging door farmaca. *Folia Medica Neerlandica* 1965; **8**: 65
- 3 **Wynn RM.** The obstetric significance of factors affecting the metabolism of bilirubin, with particular reference to the role of vitamin K. *Obstet Gynecol Surv* 1963; **18**: 333-354 [PMID: 14002133 DOI: 10.1097/00006254-196306000-00001]
- 4 **Morell A, Betlloch I, Sevil A, Bañuls J, Botella R.** Morphea-like reaction from vitamin K1. *Int J Dermatol* 1995; **34**: 201-202 [PMID: 7751098 DOI: 10.1111/j.1365-4362.1995.tb01569.x]
- 5 **Guidetti MS, Vincenzi C, Papi M, Tosti A.** Sclerodermatous skin reaction after vitamin K1 injections. *Contact Dermatitis* 1994; **31**: 45-46 [PMID: 7924294 DOI: 10.1111/j.1600-0536.1994.tb01905.x]
- 6 **Pang BK, Munro V, Kossard S.** Pseudoscleroderma secondary to phytomenadione (vitamin K1) injections: Texier's disease. *Australas J Dermatol* 1996; **37**: 44-47 [PMID: 8936071 DOI: 10.1111/j.1440-0960.1996.tb00994.x]
- 7 **García-Gavín J, Goossens A, Tennstedt D.** Allergic contact dermatitis due to cosmetics containing vitamin K1 oxide. *Contact Dermatitis* 2010; **62**: 248-250 [PMID: 20433446 DOI: 10.1111/j.1600-0536.2010.01717.x]
- 8 **Alonso-Llamazares J, Ahmed I.** Vitamin K1-induced localized scleroderma (morphea) with linear deposition of IgA in the basement membrane zone. *J Am Acad Dermatol* 1998; **38**: 322-324 [PMID: 9486707 DOI: 10.1016/s0190-9622(98)70574-2]
- 9 **Tsuboi R, Ogawa H.** Skin eruption caused by fat-soluble vitamin K injection. *J Am Acad Dermatol* 1988; **18**: 386-387 [PMID: 2964462 DOI: 10.1016/s0190-9622(88)80154-3]
- 10 **Honda M, Hattori Y, Moriyama M.** Skin eruptions caused by vitamin K. *Hifuka no Rinsho* 1970; **12**: 295-301
- 11 **Anekoji K.** Skin eruptions caused by vitamin Kt injection. *Chiryo* 1970; **52**: 1577-1587
- 12 **Riley DS, Barber MS, Kienle GS, Aronson JK, von Schoen-Angerer T, Tugwell P, Kiene H, Helfand M, Altman DG, Sox H, Werthmann PG, Moher D, Rison RA, Shamseer L, Koch CA, Sun GH, Hanaway P, Sudak NL, Kaszkin-Bettag M, Carpenter JE, Gagnier JJ.** CARE guidelines for case reports: explanation and elaboration document. *J Clin Epidemiol* 2017; **89**: 218-235 [PMID: 28529185 DOI: 10.1016/j.jclinepi.2017.04.026]
- 13 **Lauerma AI.** Immunomodulation of contact dermatitis. *Curr Probl Dermatol* 1995; **22**: 51-53 [PMID: 7587333 DOI: 10.1159/000424231]
- 14 **Ru Y, Xu XZ, Kuai L.** Study on the Drugs Used in the Treatment of Eczema by Li Bin Liangxue Qianzhen. *Zhong Yi Jichu Yi Xue Zazhi* 2018; **24**: 1773-1776
- 15 **Kuai L, Xu XZ, Ru Y.** Analysis of Li Bin's formula for treating psoriasis vulgaris with the method of cooling blood and burying Yang. *Zhong Yi Jichu Yi Xue Zazhi* 2018; **24**: 1474-1477
- 16 **Xu R, Miao X, Li X, Chen J, Zhang YN, Li B.** Effects of cooling blood restrain Yang drugs on programmed death protein-1 and its ligands in patients with psoriasis blood heat syndrome. *World Clin Drugs* 2018; **39**: 247-252
- 17 **Piguet B, Bertheuil F.** Accidents cutanes allergiques provoques par une preparation injectable de vitamine K1 synthetique. *Bull Soc Fr Dermatol Syphiligr* 1964; **71**: 486-490
- 18 **Barnes HM, Sarkany I.** Adverse skin reaction from vitamin K1. *Br J Dermatol* 1976; **95**: 653-656 [PMID: 1009013 DOI: 10.1111/j.1365-2133.1976.tb01569.x]

- 10.1111/j.1365-2133.1976.tb07041.x]
- 19 **Heydenreich G.** A further case of adverse skin reaction from vitamin K₁. *Br J Dermatol* 1977; **97**: 697 [PMID: 603752 DOI: 10.1111/j.1365-2133.1977.tb14281.x]
- 20 **Bullen AW, Miller JP, Cunliffe WJ, Losowsky MS.** Skin reactions caused by vitamin K in patients with liver disease. *Br J Dermatol* 1978; **98**: 561-565 [PMID: 148900 DOI: 10.1111/j.1365-2133.1978.tb01943.x]
- 21 **Robison JW, Odom RB.** Delayed cutaneous reaction to phytonadione. *Arch Dermatol* 1978; **114**: 1790-1792 [PMID: 736587]
- 22 **Jean-Pastor MJ, Jean Ph, Gamby T.** Accidents cutanes consecutifs it l'administration parenterale de vitamine K. *Therapie* 1981; **36**: 369-374
- 23 **Finkelstein H, Champion MC, Adam JE.** Cutaneous hypersensitivity to vitamin K₁ injection. *J Am Acad Dermatol* 1987; **16**: 540-545 [DOI: 10.1016/S0190-9622(87)70071-1]
- 24 **Joyce JP, Hood AF, Weiss MM.** Persistent cutaneous reaction to intramuscular vitamin K injection. *Arch Dermatol* 1988; **124**: 27-28 [PMID: 3337543]
- 25 **Sanders MN, Winkelmann RK.** Cutaneous reactions to vitamin K. *J Am Acad Dermatol* 1988; **19**: 699-704 [PMID: 2972759 DOI: 10.1016/S0190-9622(88)70225-x]
- 26 **Pigatto PD, Bigardi A, Fumagalli M, Altomare GF, Riboldi A.** Allergic dermatitis from parenteral vitamin K. *Contact Dermatitis* 1990; **22**: 307-308 [PMID: 2143455 DOI: 10.1111/j.1600-0536.1990.tb01615.x]
- 27 **Lee MM, Gellis S, Dover JS.** Eczematous plaques in a patient with liver failure. Fat-soluble vitamin K hypersensitivity. *Arch Dermatol* 1992; **128**: 260 [PMID: 1531408 DOI: 10.1001/archderm.128.2.257]
- 28 **Tuppai R, Tremaine R.** Cutaneous eruption from vitamin K₁ injection. *J Am Acad Dermatol* 1992; **27**: 105-106 [PMID: 1535636 DOI: 10.1016/S0190-9622(08)80816-x]
- 29 **Lemlich G, Green M, Phelps R, Lebowitz M, Don P, Gordon M.** Cutaneous reactions to vitamin K₁ injections. *J Am Acad Dermatol* 1993; **28**: 345-347 [PMID: 8436655 DOI: 10.1016/0190-9622(93)70051-t]
- 30 **Bruynzeel I, Hebeda CL, Folkers E, Bruynzeel DP.** Cutaneous hypersensitivity reactions to vitamin K: 2 case reports and a review of the literature. *Contact Dermatitis* 1995; **32**: 78-82 [PMID: 7758325 DOI: 10.1111/j.1600-0536.1995.tb00750.x]
- 31 **Balato N, Cuccurullo FM, Patruno C, Ayala F.** Adverse skin reactions to vitamin K₁: report of 2 cases. *Contact Dermatitis* 1998; **38**: 341-342 [PMID: 9687038 DOI: 10.1111/j.1600-0536.1998.tb05774.x]
- 32 **Wong DA, Freeman S.** Cutaneous allergic reaction to intramuscular vitamin K₁. *Australas J Dermatol* 1999; **40**: 147-152 [PMID: 10439527 DOI: 10.1046/j.1440-0960.1999.00348.x]
- 33 **Wilkins K, DeKoven J, Assaad D.** Cutaneous reactions associated with vitamin K₁. *J Cutan Med Surg* 2000; **4**: 164-168 [PMID: 11003724]
- 34 **Sommer S, Wilkinson SM, Peckham D, Wilson C.** Type IV hypersensitivity to vitamin K. *Contact Dermatitis* 2002; **46**: 94-96 [PMID: 11918602 DOI: 10.1034/j.1600-0536.2002.460206.x]
- 35 **Bui L, Huynh T, Lam V.** Skin reaction to subcutaneous phytonadione injections. *Am J Health Syst Pharm* 2004; **61**: 407 [PMID: 15011773 DOI: 10.1093/ajhp/61.4.407]
- 36 **Giménez-Arnau AM, Toll A, Pujol RM.** Immediate cutaneous hypersensitivity response to phytomenadione induced by vitamin K in skin diagnostic procedure. *Contact Dermatitis* 2005; **52**: 284-285 [PMID: 15899004 DOI: 10.1111/j.0105-1873.2005.0573a.x]
- 37 **Page RC, Bercovitz Z.** Dermatitis from topical application of 2-methyl- 1-4-naphthoquinone (synthetic vitamin K analogue). *Am J Med Sci* 1942; **203**: 566-569 [DOI: 10.1097/00000441-194204000-00012]
- 38 **Executive summary of disease management of drug hypersensitivity: a practice parameter.** Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. *Ann Allergy Asthma Immunol* 1999; **83**: 665-700 [PMID: 10616910]
- 39 **Lorenz W, Reimann HJ, Schmal A, Dormann P, Schwarz B, Neugebauer E, Doenicke A.** Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent. *Agents Actions* 1977; **7**: 63-67 [PMID: 67784 DOI: 10.1007/BF01964882]
- 40 **Dye D, Watkins J.** Suspected anaphylactic reaction to Cremophor EL. *Br Med J* 1980; **280**: 1353 [PMID: 7388538 DOI: 10.1136/bmj.280.6228.1353]
- 41 **Moneret-Vautrin DA, Laxenaire MC, Viry-Babel F.** Anaphylaxis caused by anti-cremophor EL IgG STS antibodies in a case of reaction to althesin. *Br J Anaesth* 1983; **55**: 469-471 [PMID: 6849729 DOI: 10.1093/bja/55.5.469]
- 42 **Aziz NA, Kamaruddin Z, Hassan Y, Jaalam K.** Vitamin K₁ induced anaphylactic shock. *J Pharm Technol* 1996; **12**: 214-216 [DOI: 10.1177/875512259601200506]
- 43 **Havel M, Müller M, Graninger W, Kurz R, Lindemayr H.** Tolerability of a new vitamin K₁ preparation for parenteral administration to adults: one case of anaphylactoid reaction. *Clin Ther* 1987; **9**: 373-379 [PMID: 3607819]
- 44 **Carton FX.** Reaction allergique au cours d'un traitement: vitamine K, + extrait de foie. *Bull Soc Fr Dermatol Syph* 1965; **72**: 228
- 45 **Texier L, Gendre P, Gauthier O.** Hypodermes sclerodermiformes lombo-fessiers induites par des injections medicamenteuses intramusculaires associees it la vitamine K. *Ann Dermatol Syph* 1972; **99**: 363-371
- 46 **Rommel A, Saurat JH.** Hypoderme Fessi-re sclerodermiforme et injections de vitamine K, /- la naissance. *Ann Pediatr (Paris)* 1982; **29**: 64-66



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

